Reports describing the successful treatment of active, steroid-resistant inflammatory bowel
disease (IBD) with leucocytapheresis first emerged about 10 years ago. Since then, several …

Background Ulcerative colitis (UC) and Crohn's disease (CD) are the major forms of
idiopathic inflammatory bowel diseases (IBD). UC and CD are both debilitating chronic …

2. Background The essential idea underlying the rationale for leucocyte apheresis treatment
in IBD is the notion that IBD is a disease brought about by an interaction between the …

Inflammatory bowel disease (IBD) is a chronic relapsing and remitting digestive disorder that
includes both Crohn's disease and ulcerative colitis. The underlying cause of IBD remains …

Intense infiltration of the intestinal mucosa by activated leukocytes is a hallmark of
inflammatory bowel disease (IBD). Therefore, removal of circulating leukocytes may be an …

Cytokines such as TNF-α have a validated role in the immunopathogensis of ulcerative
colitis (UC), and intercepting inflammatory cytokines is currently the best option for …

Therapeutic apheresis, a novel approach for immunodisorders, has been used in the last
decade for the treatment of ulcerative colitis with promising result, and represents an …

Recent studies suggest that leukocytapheresis with Cellsorba is a valuable therapy for
ulcerative colitis after failure of conventional treatment. In this study the potential of …

OBJECTIVE Leukocytapheresis (LCAP) is a method of therapeutic apheresis that removes
peripheral leukocytes. Previous studies showed that in patients with ulcerative colitis (UC) …

Active ulcerative colitis (UC) is frequently associated with infiltration of a large number of
leukocytes into the bowel mucosa. Leukocytapheresis is a novel nonpharmacologic …